Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice.

SANMAMED M; LOPEZ RODRIGUEZ I; SCHALPER KA; ONATE C; AZPILIKUETA ; RODRIGUEZ-RUIZ M; MORALES-KASTRESANA A; LABIANO S; PEREZ-GRACIA JL; MARTIN-ALGARRA S; ALFARO C; MAZZOLINI G; SARNO F; HIDALGO M; KORMAN AJ; JURE-KUNKEL M; MELERO I

CANCER RESEARCH

AMER ASSOC CANCER RESEARCH

Lugar: Philadelphia; Año: 2015

0008-5472

A current pressing need in cancer immunology is the development of preclinical model systems that are immunocompetent for the study of human tumors. Here we report the development of a humanized murine model that can be used to analyze the pharmacodynamics and antitumor properties of immunostimulatory monoclonal antibodies (mAb), in settings where the receptors targeted by the mAbs are expressed. Human lymphocytes transferred into immunodeficient mice underwent activation and redistributed to murine organs, where they exhibited cell surface expression of hCD137 and hPD-1. Systemic lymphocyte infiltrations resulted in a lethal CD4+ T cell-mediated disease (xenograft-versus-host disease), which was aggravated when murine subjects were administered clinical-grade anti-hCD137 (urelumab) and anti-hPD-1 (nivolumab). In mice engrafted with human colorectal HT-29 carcinoma cells and allogeneic human PBMCs, or with a patient-derived gastric carcinoma and peripheral blood mononuclear cells from the same patient, we found that co-administration of urelumab and nivolumab was sufficient to significantly slow tumor growth. Correlated with this result were increased numbers of activated human T lymphocytes producing IFNγ and decreased numbers of human regulatory T lymphocytes in the tumor xenografts, possibly explaining the efficacy of the therapeutic regimen. Our results offer a proof of concept for the use of humanized mouse models for surrogate efficacy and histology investigations of immune checkpoint drugs and their combinations.